Featured Publications
Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB‐J positron emission tomography study
Finnema SJ, Toyonaga T, Detyniecki K, Chen M, Dias M, Wang Q, Lin S, Naganawa M, Gallezot J, Lu Y, Nabulsi NB, Huang Y, Spencer DD, Carson RE. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB‐J positron emission tomography study. Epilepsia 2020, 61: 2183-2193. PMID: 32944949, DOI: 10.1111/epi.16653.Peer-Reviewed Original ResearchConceptsMedial temporal lobe sclerosisTemporal lobe epilepsyTLE subjectsPositron emission tomographyLobe epilepsyJ BPSynaptic vesicle protein 2APartial volume correctionTemporal lobe sclerosisPositron emission tomography studyEmission tomography studiesSeizure onset zonePromising biomarker approachJ bindingPresurgical selectionSclerotic hippocampusHippocampal asymmetryTLE patientsRegional binding patternsControl subjectsCentrum semiovaleContralateral regionsEpilepsy patientsOutcome measuresOnset zone
2024
A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease
van Dyck C, Mecca A, O’Dell R, Bartlett H, Diepenbrock N, Huang Y, Hamby M, Grundman M, Catalano S, Caggiano A, Carson R. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease. Alzheimer's Research & Therapy 2024, 16: 20. PMID: 38273408, PMCID: PMC10809445, DOI: 10.1186/s13195-024-01382-2.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAmyloid beta-PeptidesAnimalsBiomarkersFluorodeoxyglucose F18HumansMicePilot ProjectsPositron-Emission TomographyConceptsMild to moderate dementiaPositron emission tomographyAlzheimer's diseaseVolumetric MRIModerate dementiaClinical rating scalesSynaptic vesicle glycoprotein 2ACerebrospinal fluidMouse model of ADPharmacodynamic effectsPlacebo-controlled phase 1 clinical trialBiomarkers of AD pathologyClinical trialsCognitive measuresNominally significant differencesPhase 1 clinical trialModel of ADHippocampal cortexPhase 1/2 studyRating ScaleParallel-group trialSynaptic densityTrial registrationThe clinical trialPlacebo-controlledSigma-2 receptor ligands
2021
Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer’s disease: A tracer kinetic modeling study
Chen MK, Mecca AP, Naganawa M, Gallezot JD, Toyonaga T, Mondal J, Finnema SJ, Lin SF, O’Dell R, McDonald JW, Michalak HR, Vander Wyk B, Nabulsi NB, Huang Y, Arnsten AF, van Dyck CH, Carson RE. Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer’s disease: A tracer kinetic modeling study. Cerebrovascular And Brain Metabolism Reviews 2021, 41: 2395-2409. PMID: 33757318, PMCID: PMC8393289, DOI: 10.1177/0271678x211004312.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlzheimer DiseaseFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedPositron-Emission TomographyConceptsSynaptic densityMedial temporal regionsAlzheimer's diseaseNeocortical regionsTemporal regionsRelative outcome measuresMedial temporal lobeVivo PET imagingJ bindingOutcome measuresTemporal lobeMagnitude of reductionCN participantsBrain regionsAD participantsDiseasePET imagingConcordant reductionNormal participantsSynaptic vesiclesPerfusionMetabolismSuitable markerParticipantsSimilar pattern
2019
Measuring the effects of ketamine on mGluR5 using [18F]FPEB and PET
Holmes SE, Gallezot JD, Davis MT, DellaGioia N, Matuskey D, Nabulsi N, Krystal JH, Javitch JA, DeLorenzo C, Carson RE, Esterlis I. Measuring the effects of ketamine on mGluR5 using [18F]FPEB and PET. Cerebrovascular And Brain Metabolism Reviews 2019, 40: 2254-2264. PMID: 31744389, PMCID: PMC7585925, DOI: 10.1177/0271678x19886316.Peer-Reviewed Original ResearchConceptsEffects of ketamineKetamine infusionGlutamate transmissionMetabotropic glutamate receptor 5Ketamine-induced effectsKetamine-induced changesGlutamate receptor 5Promising treatment targetDrug challenge studiesTwo-tissue compartment modelMGluR5 radioligandBlood pressureMGluR5 availabilityBaseline scanOutcome measuresHealthy subjectsHeart ratePsychiatric disordersReceptor 5Modulatory effectsMGluR5Treatment targetsChallenge studiesArterial input functionChallenge paradigmData-driven voluntary body motion detection and non-rigid event-by-event correction for static and dynamic PET
Lu Y, Gallezot JD, Naganawa M, Ren S, Fontaine K, Wu J, Onofrey JA, Toyonaga T, Boutagy N, Mulnix T, Panin VY, Casey ME, Carson RE, Liu C. Data-driven voluntary body motion detection and non-rigid event-by-event correction for static and dynamic PET. Physics In Medicine And Biology 2019, 64: 065002. PMID: 30695768, DOI: 10.1088/1361-6560/ab02c2.Peer-Reviewed Original Research
2015
Imaging human brown adipose tissue under room temperature conditions with 11C-MRB, a selective norepinephrine transporter PET ligand
Hwang JJ, Yeckel CW, Gallezot JD, Aguiar RB, Ersahin D, Gao H, Kapinos M, Nabulsi N, Huang Y, Cheng D, Carson RE, Sherwin R, Ding YS. Imaging human brown adipose tissue under room temperature conditions with 11C-MRB, a selective norepinephrine transporter PET ligand. Metabolism 2015, 64: 747-755. PMID: 25798999, PMCID: PMC4408242, DOI: 10.1016/j.metabol.2015.03.001.Peer-Reviewed Original ResearchConceptsBrown adipose tissueDistribution volume ratioSympathetic nervous systemAdipose tissueRole of BATCold stimulationFDG PET-CT imagingNorepinephrine transporterSupraclavicular brown adipose tissueHuman brown adipose tissueTotal body fatLean body massCold-stimulated conditionsBody temperaturePET-CT imagingBioelectrical impedance analysisCore body temperatureFDG uptakePET-CTOccipital cortexBody fatNervous systemBody compositionPET ligandBasal state
1988
A method for postinjection PET transmission measurements with a rotating source.
Carson RE, Daube-Witherspoon ME, Green MV. A method for postinjection PET transmission measurements with a rotating source. Journal Of Nuclear Medicine 1988, 29: 1558-67. PMID: 3261786.Peer-Reviewed Original ResearchMeSH KeywordsDeoxyglucoseFluorine RadioisotopesFluorodeoxyglucose F18HumansModels, StructuralTomography, Emission-Computed
1985
Alternative Statistical Models for the Examination of Clinical Positron Emission Tomography/Fluorodeoxyglucose Data
Clark C, Carson R, Kessler R, Margolin R, Buchsbaum M, DeLisi L, King C, Cohen R. Alternative Statistical Models for the Examination of Clinical Positron Emission Tomography/Fluorodeoxyglucose Data. Cerebrovascular And Brain Metabolism Reviews 1985, 5: 142-150. PMID: 3871782, DOI: 10.1038/jcbfm.1985.18.Peer-Reviewed Original Research